(Q43264900)

17 November 2017

title

Binasal visual field defects are not specific to vigabatrin (English)

1 reference

17 November 2017

8

Martin J Brodie

1 reference

17 November 2017

5

Linda J Stephen

1 reference

17 November 2017

2

Graeme J Sills

1 reference

17 November 2017

Pedro Gonzalez

1

1 reference

17 November 2017

Stuart Parks

3

1 reference

17 November 2017

Kevin Kelly

4

1 reference

17 November 2017

David Keating

6

1 reference

17 November 2017

Gordon N Dutton

7

1 reference

17 November 2017

publication date

7 October 2009

1 reference

17 November 2017

1 reference

17 November 2017

volume

16

1 reference

17 November 2017

issue

3

1 reference

17 November 2017

page(s)

521-526

1 reference

17 November 2017

cites work

New antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.09.003

gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.09.003

The new antiepileptic drugs: a systematic review of their efficacy and tolerability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.09.003

Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.09.003

Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.09.003

Randomized trial of vigabatrin in patients with infantile spasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.09.003

Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.09.003

The potential for vigabatrin-induced intramyelinic edema in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.09.003

Severe persistent visual field constriction associated with vigabatrin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.09.003

Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.09.003

Vigabatrin and epilepsy: lessons learned

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.09.003

The wide field multifocal ERG reveals a retinal defect caused by vigabatrin toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.09.003

Peripheral retinal dysfunction in patients taking vigabatrin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.09.003

Development of the 25-item National Eye Institute Visual Function Questionnaire

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.09.003

Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.09.003

Recovery of visual field constriction following discontinuation of vigabatrin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.09.003

Visual function loss from vigabatrin: effect of stopping the drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.09.003

Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.09.003

Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.09.003

Neuropsychological and behavioral effects of antiepilepsy drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.09.003

Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin: ocular safety pilot results.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2009.09.003

10.1016/J.YEBEH.2009.09.003

7 January 2021

Identifiers

DOI

1 reference

17 November 2017

1 reference